Related Experiment Video

Updated: Jun 22, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

19.7K

The Curious Role of PAI-1 in Severe Obstructive Sleep Apnea

Tea Friščić1, Edvard Galić1,2, Domagoj Vidović3

  • 1Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia.

Biomedicines
|June 27, 2024
PubMed

Insights

Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) did not significantly alter PAI-1 levels but showed a trend toward improved fibrinolysis. D-dimer increased and fibrinogen decreased post-therapy.

Area of Science:

  • Cardiovascular Medicine
  • Sleep Medicine
  • Hematology

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) is implicated in fibrinolysis, atherogenesis, senescence, and inflammation.
  • Obstructive sleep apnea (OSA) is linked to elevated PAI-1 and cardiovascular disease (CVD).

Purpose of the Study:

  • To investigate the impact of CPAP therapy on coagulation parameters and PAI-1 in severe OSA patients.

Main Methods:

  • Prospective, controlled study of 57 newly diagnosed severe OSA patients.
  • Analysis of coagulation parameters and PAI-1 before and after 6 months of CPAP therapy in 37 patients with good adherence.

Main Results:

  • A significant increase in D-dimer (p=0.0282) and a significant decrease in fibrinogen (p=0.0075) were observed post-CPAP.
  • No significant difference in PAI-1 levels was found before and after CPAP therapy (p=0.9367).

Conclusions:

  • CPAP therapy in severe OSA patients demonstrated a tendency towards improved fibrinolytic capacity.
  • While coagulation markers shifted, PAI-1 levels remained unchanged, suggesting complex regulatory mechanisms in OSA treatment.

Keywords:
atherogenesiscontinuous positive airway pressurefibrinolytic capacityobstructive sleep apneaplasminogen activator inhibitor-1

More Related Videos

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

755
Image Acquisition using Portable Sonography for Emergency Airway Management07:31

Image Acquisition using Portable Sonography for Emergency Airway Management

Published on: September 28, 2022

2.3K

Related Concept Videos

Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
140
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
195
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Mechanical Ventilation III: Noninvasive Ventilation01:23

Mechanical Ventilation III: Noninvasive Ventilation

Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
97
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152